# US 2019/0375756 A1 · Salt Type And Crystal Type Of 4h-Pyrazolo [1, 5-Alpha] Benzimidazole Compound And Preparation Method And Intermediate Thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0375756 A1
- Document ID: US20190375756A1
- Status: Published application
- Kind: A1
- Application number: 16/548,303
- Filed: 2019-08-22
- Published: 2019-12-12
- Earliest claimed: 2015-09-30
- Assignees: Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.; Humanwell Healthcare (Group) Co., Ltd.
- Applicants: Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.; Humanwell Healthcare (Group) Co., Ltd.
- Inventors: Xuehai WANG; Charles Z. DING; Jie SHEN; Shuhui CHEN; Lie LI; Gang LI; Yong XU; Cailin WANG; Ronghua TU; Jimeng WANG; Yang YUE; Biao DENG; Hailiang CHEN; Hui LIU; Wenjie SUN; Cong WANG; Lu HUANG; Zheng WANG; Weidong LI
- Web page: https://patentgrep.com/patent/US20190375756A1

## CPC

- C07D 487/04: Ortho-condensed systems
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07C 57/145: Maleic acid
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- C07B 2200/13: Crystalline forms, e.g. polymorphs
- Y02P 20/55: Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)
- Y02P: CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS

## Abstract

Disclosed in the present invention are a salt type and crystal type of 4H-pyrazolo[1, 5-alpha]benzimidazole compound and the preparation method and intermediate thereof.

## Claims

### Claim 1

A compound 2,

### Claim 2 (depends on 1)

A method for inhibiting PARP activity in a subject thereof, comprising: administering an effective amount of compound 2 as defined in claim 1 to the subject.

### Claim 3 (depends on 1)

A process for preparing compound 2 as defined in claim 1, comprising:
wherein,
HA is maleic acid;
R is isopropyl.

### Claim 4 (depends on 3)

The process as defined in claim 3, wherein, the reaction solvent is an alcoholic solvent and/or a mixed solvent containing an alcoholic solvent and water.

### Claim 5 (depends on 4)

The process as defined in claim 4, wherein, the volume ratio of the alcoholic solvent to water is 1:0.05-0.1.

### Claim 6 (depends on 4)

The process as defined in claim 4, wherein, the alcoholic solvent is selected from methanol, ethanol and/or isopropanol.

### Claim 7 (depends on 4)

The process as defined in claim 4, wherein, the amount of the reaction solvent is 5 to 20 times the weight of the compound (VII).

### Claim 8 (depends on 7)

The process as defined in claim 7, wherein, the amount of the reaction solvent is 8 to 12 times the weight of the compound (VII).

### Claim 9 (depends on 3)

The process as defined in claim 3, wherein, the mole ratio of the compound (VII) to the reagent HA is 1:0.5-2.

### Claim 10 (depends on 9)

The process as defined in claim 9, wherein, the mole ratio of the compound (VII) to the reagent HA is 1:1.05-1.2.

### Claim 11 (depends on 3)

The process as defined in claim 3, wherein, the reaction is conducted at 50 to 100° C.

### Claim 12 (depends on 11)

The process as defined in claim 11, wherein, the reaction is conducted at 60 to 80° C.
